Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Am J Hematol
; 98(1): E15-E19, 2023 01.
Article
in En
| MEDLINE
| ID: mdl-35604280
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Myeloma
Limits:
Humans
Language:
En
Journal:
Am J Hematol
Year:
2023
Type:
Article
Affiliation country:
Greece